Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs XPO Inc. Common Stock — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while XPO Inc. Common Stock trades at $187.74 (market cap $21.21B). The key difference: XPO Inc. Common Stock is far larger — about 2.8× Spyre Therapeutics Inc. Common Stock's market cap, and XPO Inc. Common Stock is more actively traded (663,957 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and XPO Inc. Common Stock for 6 Days on average.
| SYRE | XPO | |
|---|---|---|
Market Cap | $7.52B | $21.21B |
Volume | 1,441,031 | 663,957 |
Sector | Health | Industrials |
52-Week High | $108.92 | $228.37 |
52-Week Low | $22.18 | $123.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.52B | $24.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XPO trades at $181.15, up 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $8.6B in 2026, and net income margin improved to 4.71%. Recent news highlights operational expansions and industry recognition, such as new service centers and a FreightTech 100 award.
The outlook is positive with strong analyst support—71.9% recommend Buy and a consensus price target of $227.64 implies ~26% upside. Key risks include high valuation multiples (P/E 53.44) and exposure to freight market volatility. Earnings growth and margin improvements are primary catalysts, but investors should monitor competitive pressures and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
